In a 32‑week pregnant woman weighing 77 kg with overt (pre‑gestational) diabetes, what basal and bolus insulin doses should be prescribed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Insulin Dosing for 32-Week Pregnant Woman with Overt Diabetes

For a 77 kg woman at 32 weeks gestation with pre-existing diabetes, start with approximately 0.9-1.0 units/kg/day total daily dose (69-77 units/day), distributing 25-30% as basal insulin (17-23 units) and 70-75% as bolus insulin (52-58 units divided across three meals).

Rationale and Dosing Algorithm

At 32 weeks gestation, insulin resistance is near its peak, requiring substantially higher doses than pre-pregnancy levels 1, 2. The evidence consistently shows that:

Total Daily Dose Calculation

  • Starting point: 0.9-1.0 units/kg/day at this gestational age
  • For 77 kg: approximately 69-77 units total daily
  • This represents roughly double to triple the pre-pregnancy requirement 3, 1

Basal vs. Bolus Distribution

The critical principle: A small proportion should be basal, with the greater proportion as prandial (bolus) insulin 4. Specifically:

  • Basal insulin: 25-30% of total daily dose = 17-23 units once daily

    • Use long-acting insulin (NPH, detemir, or glargine)
    • Given at bedtime or morning, depending on fasting glucose patterns
  • Bolus insulin: 70-75% of total daily dose = 52-58 units

    • Divide across three meals based on carbohydrate content
    • Typical distribution:
      • Breakfast: 40% of bolus dose (21-23 units) - highest insulin resistance in morning
      • Lunch: 30% of bolus dose (16-17 units)
      • Dinner: 30% of bolus dose (16-17 units)
    • Use rapid-acting insulin (lispro, aspart, or regular insulin)

This distribution reflects the metabolic physiology of pregnancy, where postprandial hyperglycemia predominates due to diabetogenic placental hormones 4. Research confirms that bolus insulin increases from approximately 50% pre-pregnancy to 75% by 36 weeks 5.

Titration Strategy

Adjust insulin every 2-3 days based on glucose monitoring 6, 2:

  • Fasting glucose >95 mg/dL: Increase basal insulin by 10-20%
  • 1-hour postprandial >140 mg/dL or 2-hour >120 mg/dL: Increase corresponding meal bolus by 10-20%
  • Hypoglycemia <70 mg/dL: Decrease relevant insulin dose by 10-20%

Weekly or biweekly increases are typically needed in the second and third trimesters to match rapidly increasing insulin resistance 4.

Glycemic Targets

Monitor pre- and postprandial glucose to achieve 6, 2, 6:

  • Fasting: 70-95 mg/dL (3.9-5.3 mmol/L)
  • 1-hour postprandial: 110-140 mg/dL (6.1-7.8 mmol/L)
  • 2-hour postprandial: 100-120 mg/dL (5.6-6.7 mmol/L)
  • A1C target: <6% if achievable without significant hypoglycemia

Critical Considerations

Common pitfalls to avoid:

  1. Underestimating bolus needs: The predominant insulin resistance in pregnancy is postprandial, not fasting. Most women need 70-75% of their total dose as bolus insulin by the third trimester 5.

  2. Insufficient dose escalation: Insulin requirements plateau around 30-36 weeks but remain elevated until delivery 7, 8. Don't hesitate to increase doses substantially.

  3. Rigid dosing: Adjust bolus insulin based on actual carbohydrate intake and pre-meal glucose levels. Consider insulin-to-carbohydrate ratios (typically 1 unit per 10-15g carbohydrate in third trimester).

  4. Missing hypoglycemia risk: Pregnancy is ketogenic, and DKA can occur at lower glucose levels. Ensure patient has ketone strips and knows when to check 9.

Insulin safety in pregnancy: All insulins are pregnancy category B except glargine and glulisine (category C), though all are used safely in clinical practice 4.

Referral consideration: Given the complexity of insulin management in pregnancy, referral to a specialized diabetes-in-pregnancy center is recommended if available 4.

Related Questions

What is the appropriate insulin regimen, including type, dose, and timing, for a pregnant woman?
For a 45-year-old male weighing 98.4 kg with newly diagnosed diabetes (A1C 14.5%) on an insulin drip titrated to 13 units per hour, receiving 1 unit per 10 g carbohydrate for an 80‑g carbohydrate load, what should his insulin‑to‑carbohydrate ratio be?
For a 25‑year‑old woman at 28 weeks gestation with type 2 diabetes, weight 114 kg, on insulin glargine (Lantus) 32 U daily, insulin‑to‑carbohydrate ratio 1 U:5 g, and insulin sensitivity factor 1 U:25 mg/dL, who ate 55 g carbohydrate at 6 pm and had blood glucose 183 mg/dL at 9 pm and fasting glucose 187 mg/dL, how should her insulin sensitivity factor, insulin‑to‑carbohydrate ratio, and basal insulin dose be adjusted?
A 28‑week‑gestation pregnant woman weighing 114 kg has a fasting blood glucose of 157 mg/dL while on insulin glargine (Lantus) 40 units daily; how much should the insulin glargine dose be increased?
A 28‑week pregnant woman with type 2 diabetes mellitus, weight 114 lb (≈52 kg) and A1c 6.7%, what should her insulin glargine (Lantus) dose, insulin sensitivity factor (ISF), and insulin‑to‑carbohydrate ratio (ICR) be?
What contact precautions should be implemented for neonates suspected of congenital cytomegalovirus infection?
What questions should I ask a newly referred patient with chronic obstructive pulmonary disease (COPD) during a pulmonary referral?
What volume of pleural effusion requires aspiration?
In a previously healthy 22‑year‑old man presenting with acute fever, confusion, nuchal rigidity, and cerebrospinal fluid showing a neutrophilic pleocytosis of approximately 2800 cells/µL, elevated protein of 150 mg/dL, low glucose of 30 mg/dL with serum glucose 95 mg/dL, and a negative Gram stain, what is the most likely causative pathogen?
If the JC virus antibody test is negative, can natalizumab be continued?
What are the mechanism of action, clinical indications, dosing regimen, and common adverse effects of pregabalin?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.